Grand Challenges in Biosensors and Biomolecular Electronics

A Review on Biosensors for Quantification of MCP-1 as a Potential Biomarker in Diseases

Monocyte chemoattractant protein-1 (MCP-1) as a chemokine is essential for inflammation-related processes. It regulates immunological responses and cell migration, which contribute to inflammation. Many disorders are exacerbated by this chemokine, which attracts or grows other inflammatory cells, including monocytes/macrophages, at the site of infection or tissue injury. The elevated concentrations of MCP-1 are associated with the pathogenesis of many diseases, such as cancer, cardiovascular disease, kidney disease, and neuroinflammatory disease. Therefore, monitoring this inflammatory biomarker in the body has been recommended and strongly advised to make an accurate diagnosis and prognosis. Although MCP-1 is of great importance in disease processes, few biosensing approaches are specifically designed to detect this molecule. These are often electrochemical and optical techniques. Rapid and accurate diagnosis of inflammatory diseases by identifying biomarkers has had a great effect on the advancement of biosensors. Improved biosensor technology expansion prevents excessive prices and low sensitivity, enabling quick and correct diagnosis and tracking of disease processes. This review will concentrate on the biological functions of MCP-1, its significance in different disorders, and the features and applications of biosensors designed for MCP-1 detection and quantification.

Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access

The advent of advanced biomolecular technologies for detecting molecular and genomic signatures of individual tumors has transformed oncology care, introducing proven methodologies that can inform treatment with matched targeted therapies and predict response at the individual patient level. However, access to these technologies has been hampered by multiple barriers, most notably price and obtainability. Other barriers include lack of knowledge of available technologies, concerns about value, and outdated infrastructures that impede critical operations within the clinic or laboratory. Accessibility barriers to advanced biomolecular testing are critically important to patient care, as new technological advances in molecular medicine continue to outpace the implementation of solutions. Given the proven evidence for improved patient outcomes with precision oncology medicines, it is imperative to understand the value afforded by these technologies. The purpose of this narrative review is to describe existing and emerging barriers to access and present a "roadmap to access" that will facilitate the urgently needed discussions to identify solutions for improving access. Implementation of these solutions will raise awareness of available technologies and treatments and their prognostic significance, improve evidence collection for demonstration of value, and fortify clinical and laboratory infrastructure and operations.

MXene-Based Electrochemical Biosensors: Advancing Detection Strategies for Biosensing (2020-2024)

MXenes, a class of two-dimensional materials, have emerged as promising candidates for developing advanced electrochemical biosensors due to their exceptional electrical conductivity, large surface area, and rich surface chemistry. These unique properties enable high sensitivity, rapid response, and versatile functionalization, making MXene-based biosensors highly suitable for detecting biomolecules and pathogens in biomedical applications. This review explores recent advancements in MXene-based electrochemical biosensors from 2020 to 2024, focusing on their design principles, fabrication strategies, and integration with microfluidic platforms for enhanced performance. The potential of MXene sensors to achieve real-time and multiplexed detection is highlighted, alongside the associated challenges. Emphasis is placed on the role of MXenes in addressing critical needs in disease diagnostics, personalized medicine, and point-of-care testing, providing insights into future trends and transformative possibilities in the field of biomedical sensing technologies.

Variable gain DNA nanostructure charge amplifiers for biosensing

Electronic measurements of engineered nanostructures comprised solely of DNA (DNA origami) enable new signal conditioning modalities for use in biosensing. DNA origami, designed to take on arbitrary shapes and allow programmable motion triggered by conjugated biomolecules, have sufficient mass and charge to generate a large electrochemical signal. Here, we demonstrate the ability to electrostatically control the DNA origami conformation, and thereby the resulting signal amplification, when the structure binds a nucleic acid analyte. Critically, unlike previous studies that employ DNA origami to amplify an electrical signal, we show that the conformation changes under an applied field are reversible. This applied field also simultaneously accelerates structural transitions above the rate determined by thermal motion. We tuned this property of the structures to achieve a response that was ≈2 × 104 times greater (i.e., a gain or amplification) than the value from DNA hybridization under similar conditions. Because this signal amplification is independent of DNA origami-analyte interactions, our approach is agnostic of the end application. Furthermore, since large signal changes are only triggered in response to desirable interactions, we minimize the deleterious effects of non-specific binding. The above benefits of self-assembled DNA origami make them ideally suited for multiplexed biosensing when paired with highly parallel electronic readout.

AI-Based Metamaterial Design

The use of metamaterials in various devices has revolutionized applications in optics, healthcare, acoustics, and power systems. Advancements in these fields demand novel or superior metamaterials that can demonstrate targeted control of electromagnetic, mechanical, and thermal properties of matter. Traditional design systems and methods often require manual manipulations which is time-consuming and resource intensive. The integration of artificial intelligence (AI) in optimizing metamaterial design can be employed to explore variant disciplines and address bottlenecks in design. AI-based metamaterial design can also enable the development of novel metamaterials by optimizing design parameters that cannot be achieved using traditional methods. The application of AI can be leveraged to accelerate the analysis of vast data sets as well as to better utilize limited data sets via generative models. This review covers the transformative impact of AI and AI-based metamaterial design for optics, acoustics, healthcare, and power systems. The current challenges, emerging fields, future directions, and bottlenecks within each domain are discussed.

Development of epistatic YES and AND protein logic gates and their assembly into signalling cascades

The construction and assembly of artificial allosteric protein switches into information and energy processing networks connected to both biological and non-biological systems is a central goal of synthetic biology and bionanotechnology. However, designing protein switches with the desired input, output and performance parameters is challenging. Here we use a range of reporter proteins to demonstrate that their chimeras with duplicated receptor domains produce YES gate protein switches with large (up to 9,000-fold) dynamic ranges and fast (minutes) response rates. In such switches, the epistatic interactions between largely independent synthetic allosteric sites result in an OFF state with minimal background noise. We used YES gate protein switches based on β-lactamase to develop quantitative biosensors of therapeutic drugs and protein biomarkers. Furthermore, we demonstrated the reconfiguration of YES gate switches into AND gate switches controlled by two different inputs, and their assembly into signalling networks regulated at multiple nodes.

Digital Quantification Method for Sensitive Point-of-Care Detection of Salivary Uric Acid Using Smartphone-Assisted μPADs

Uric acid (UA) is an important biomarker for many diseases. A sensitive point-of-care (POC) testing platform is designed for the digital quantification of salivary UA based on a colorimetric reaction on an easy-to-build smartphone-assisted microfluidic paper-based analytical device (SμPAD). UA levels are quantified according to the color intensity of Prussian blue on the SμPAD with the aid of a MATLAB code or a smartphone APP. A color correction method is specifically applied to exclude the light effect. Together with the engineering design of SμPADs, the background calibration function with the APP increases the UA sensitivity by 100-fold to reach 0.1 ppm with a linear range of 0.1-200 ppm. The assay time is less than 10 min. SμPADs demonstrate a correlation of 0.97 with a commercial UA kit for the detection of salivary UA in clinical samples. SμPADs provide a sensitive, fast, affordable, and reliable tool for the noninvasive POC quantification of salivary UA for early diagnosis of abnormal UA level-associated health conditions.